Neuberger Berman Group’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-179,500
| Closed | -$3.38M | – | 1639 |
|
|
2019
Q3 | $3.38M | Sell |
179,500
-74,050
| -29% | -$847K | ﹤0.01% | 912 |
|
|
2019
Q2 | $2.98M | Buy |
253,550
+119,300
| +89% | +$1.44M | ﹤0.01% | 945 |
|
|
2019
Q1 | $1.83M | Buy |
134,250
+123,750
| +1,179% | +$1.6M | ﹤0.01% | 989 |
|
|
2018
Q4 | $108K | Sell |
10,500
-19,500
| -65% | -$250K | ﹤0.01% | 1535 |
|
|
2018
Q3 | $500K | Buy |
30,000
+20,000
| +200% | +$361K | ﹤0.01% | 1318 |
|
|
2018
Q2 | $158K | Buy |
+10,000
| New | +$152K | ﹤0.01% | 1666 |
|
|
2016
Q4 | – | Sell |
-14,500
| Closed | -$475K | – | 1677 |
|
|
2016
Q3 | $475K | Sell |
14,500
-5,500
| -28% | -$167K | ﹤0.01% | 1279 |
|
|
2016
Q2 | $499K | Buy |
+20,000
| New | +$541K | ﹤0.01% | 1247 |
|
|
2016
Q1 | – | Sell |
-18,000
| Closed | -$595K | – | 1547 |
|
|
2015
Q4 | $595K | Buy |
+18,000
| New | +$609K | ﹤0.01% | 1232 |
|
|
2015
Q3 | – | Sell |
-20,000
| Closed | -$1.06M | – | 1617 |
|
|
2015
Q2 | $1.06M | Buy |
+20,000
| New | +$727K | ﹤0.01% | 1197 |
|
|
2015
Q1 | – | Sell |
-22,450
| Closed | -$653K | – | 1687 |
|
|
2014
Q4 | $653K | Buy |
+22,450
| New | +$403K | ﹤0.01% | 1303 |
|
Neuberger Berman Group's ALDR Position: Q4 2019 in Review
Neuberger Berman Group sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 179,500 shares — an estimated $3.38M sold.
Neuberger Berman Group first reported a position in ALDR in Q4 2014 and held it in 11 quarters. The position peaked at $3.38M in Q3 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Neuberger Berman Group reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Neuberger Berman Group sold 179,500 Alder Biopharmaceuticals shares in Q4 2019, an estimated $3.38M.
- Neuberger Berman Group first reported a position in Alder Biopharmaceuticals in Q4 2014 and held it in 11 quarters.
- Neuberger Berman Group's Alder Biopharmaceuticals position peaked at $3.38M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Neuberger Berman Group's 13F filing for Q4 2019, filed 12 Feb 2020.